BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1206 related articles for article (PubMed ID: 15217410)

  • 1. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
    Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Gonzalez Molina M; Hernandez D
    Transplant Proc; 2009; 41(6):2137-8. PubMed ID: 19715855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus in chronic allograft nephropathy in pediatric recipients.
    Ibáñez JP; Monteverde ML; Diaz MA; Goldberg J; Turconi AF
    Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
    Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
    Gutiérrez-Dalmau A; Sánchez-Fructuoso A; Sanz-Guajardo A; Mazuecos A; Franco A; Rial MC; Iranzo P; Torregrosa JV; Oppenheimer F; Campistol JM
    Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J; Lerman M; Magee MJ; Dewey TM; Herbert M; Mack MJ
    J Heart Lung Transplant; 2005 Nov; 24(11):1863-7. PubMed ID: 16297793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
    Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.